FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1566100238> ?p ?o ?g. }

• W1566100238 endingPage "90" @default.
• W1566100238 startingPage "81" @default.
• W1566100238 abstract "Chondroitin sulfate proteoglycan 4 (CSPG4), a highly immunogenic melanoma tumor antigen, is a potential target for antibody-based immunotherapy. The mechanism by which CSPG4 affects melanoma progression is only partly understood, in particular the involvement of other receptor tyrosine kinases and the tumor microenvironment. We have previously reported on a mimotope-based vaccine against CSPG4 in a human melanoma xenograft model that resulted in reduction of tumor growth. Herein we describe the influence of hypoxia on the response to polyclonal anti-CSPG4-antibodies induced by this vaccine in combination with the BRAF inhibitor vemurafenib to enhance therapeutic efficacy by simultaneously targeting multiple signaling pathways. Melanoma cells were treated with polyclonal anti-CSPG4-antibodies and vemurafenib. Proliferation, migration and invasion were evaluated in a real-time setting in the impedance-based x-CELLigence® system. Western blotting and quantitative PCR arrays were used to determine protein and mRNA expression of hypoxia inducible factor 1α (HIF1α), carbonic anhydrase IX (CAIX) and signaling pathway proteins. A melanoma xenograft model was used to detect HIF1α and CAIX expression in vivo. Hypoxia enhanced the antiproliferative response to vemurafenib. The migration and invasion capacities of vemurafenib-treated melanoma cells were increased, in spite of vemurafenib-decreased expression of HIF1α and CAIX. Polyclonal anti-CSPG4-antibodies reduced the Transwell migration of vemurafenib-treated, BRAF V600E-mutant and CSPG4-expressing melanoma cells in hypoxia. This was associated with the downregulation of phosphorylated AKT, a kinase contributing to tumor cell migration. Our results highlight CSPG4 as a potential target for modulating treatment resistance to vemurafenib induced by the hypoxic microenvironment." @default.
• W1566100238 created "2016-06-24" @default.
• W1566100238 creator A5001544400 @default.
• W1566100238 creator A5007128413 @default.
• W1566100238 creator A5009309257 @default.
• W1566100238 creator A5023172362 @default.
• W1566100238 creator A5038422439 @default.
• W1566100238 creator A5040611651 @default.
• W1566100238 creator A5043888406 @default.
• W1566100238 creator A5048935719 @default.
• W1566100238 date "2015-05-18" @default.
• W1566100238 modified "2023-10-17" @default.
• W1566100238 title "Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia" @default.
• W1566100238 cites W1494330915 @default.
• W1566100238 cites W1498470979 @default.
• W1566100238 cites W1970323663 @default.
• W1566100238 cites W1971866921 @default.
• W1566100238 cites W1972960024 @default.
• W1566100238 cites W1974889077 @default.
• W1566100238 cites W1983080825 @default.
• W1566100238 cites W1983770566 @default.
• W1566100238 cites W1985424846 @default.
• W1566100238 cites W1985928174 @default.
• W1566100238 cites W1988009043 @default.
• W1566100238 cites W1996765884 @default.
• W1566100238 cites W2001348339 @default.
• W1566100238 cites W2010545765 @default.
• W1566100238 cites W2013735638 @default.
• W1566100238 cites W2019602861 @default.
• W1566100238 cites W2027278544 @default.
• W1566100238 cites W2033363278 @default.
• W1566100238 cites W2034937288 @default.
• W1566100238 cites W2049112891 @default.
• W1566100238 cites W2055788350 @default.
• W1566100238 cites W2061339803 @default.
• W1566100238 cites W2061368965 @default.
• W1566100238 cites W2067680442 @default.
• W1566100238 cites W2084704553 @default.
• W1566100238 cites W2085551560 @default.
• W1566100238 cites W2094666702 @default.
• W1566100238 cites W2098685167 @default.
• W1566100238 cites W2099869894 @default.
• W1566100238 cites W2102448788 @default.
• W1566100238 cites W2102610918 @default.
• W1566100238 cites W2106543129 @default.
• W1566100238 cites W2111180747 @default.
• W1566100238 cites W2112887207 @default.
• W1566100238 cites W2116629325 @default.
• W1566100238 cites W2124896191 @default.
• W1566100238 cites W2128542677 @default.
• W1566100238 cites W2132719707 @default.
• W1566100238 cites W2136348963 @default.
• W1566100238 cites W2138414111 @default.
• W1566100238 cites W2147233186 @default.
• W1566100238 cites W2148110870 @default.
• W1566100238 cites W2150032631 @default.
• W1566100238 cites W2156599555 @default.
• W1566100238 cites W2165241843 @default.
• W1566100238 cites W2171367970 @default.
• W1566100238 doi "https://doi.org/10.3892/ijo.2015.3010" @default.
• W1566100238 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4485656" @default.
• W1566100238 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25997619" @default.
• W1566100238 hasPublicationYear "2015" @default.
• W1566100238 type Work @default.
• W1566100238 sameAs 1566100238 @default.
• W1566100238 citedByCount "12" @default.
• W1566100238 countsByYear W15661002382017 @default.
• W1566100238 countsByYear W15661002382018 @default.
• W1566100238 countsByYear W15661002382020 @default.
• W1566100238 countsByYear W15661002382021 @default.
• W1566100238 countsByYear W15661002382022 @default.
• W1566100238 countsByYear W15661002382023 @default.
• W1566100238 crossrefType "journal-article" @default.
• W1566100238 hasAuthorship W1566100238A5001544400 @default.
• W1566100238 hasAuthorship W1566100238A5007128413 @default.
• W1566100238 hasAuthorship W1566100238A5009309257 @default.
• W1566100238 hasAuthorship W1566100238A5023172362 @default.
• W1566100238 hasAuthorship W1566100238A5038422439 @default.
• W1566100238 hasAuthorship W1566100238A5040611651 @default.
• W1566100238 hasAuthorship W1566100238A5043888406 @default.
• W1566100238 hasAuthorship W1566100238A5048935719 @default.
• W1566100238 hasBestOaLocation W15661002381 @default.
• W1566100238 hasConcept C203014093 @default.
• W1566100238 hasConcept C2776131300 @default.
• W1566100238 hasConcept C2777658100 @default.
• W1566100238 hasConcept C2780394083 @default.
• W1566100238 hasConcept C2994587330 @default.
• W1566100238 hasConcept C502942594 @default.
• W1566100238 hasConcept C86803240 @default.
• W1566100238 hasConceptScore W1566100238C203014093 @default.
• W1566100238 hasConceptScore W1566100238C2776131300 @default.
• W1566100238 hasConceptScore W1566100238C2777658100 @default.
• W1566100238 hasConceptScore W1566100238C2780394083 @default.
• W1566100238 hasConceptScore W1566100238C2994587330 @default.
• W1566100238 hasConceptScore W1566100238C502942594 @default.
• W1566100238 hasConceptScore W1566100238C86803240 @default.
• W1566100238 hasIssue "1" @default.
• W1566100238 hasLocation W15661002381 @default.

• next